nemiralisib   Click here for help

GtoPdb Ligand ID: 9425

Synonyms: compound 2 [PMID: 26301626] | GSK-2269557 | GSK2269557
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Nemiralisib (GSK2269557) is a PI3K inhibitor with selectivity for PI3Kδ over the other related isoforms [1]. The compound is active via inhalation and is being evaluated for its potential in respiratory inflammation. May be administered or used experimentally as the hydrochloride salt (PubChem CID 49784084). In the original study by Down et al. (2015) compound 3 (GSK2292767) was developed as a follow-up compound with reduced hERG activity and minimised systemic exposure [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 76.98
Molecular weight 440.23
XLogP 4.31
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC(N1CCN(CC1)Cc1cnc(o1)c1cc(cc2c1cn[nH]2)c1cccc2c1cc[nH]2)C
Isomeric SMILES CC(N1CCN(CC1)Cc1cnc(o1)c1cc(cc2c1cn[nH]2)c1cccc2c1cc[nH]2)C
InChI InChI=1S/C26H28N6O/c1-17(2)32-10-8-31(9-11-32)16-19-14-28-26(33-19)22-12-18(13-25-23(22)15-29-30-25)20-4-3-5-24-21(20)6-7-27-24/h3-7,12-15,17,27H,8-11,16H2,1-2H3,(H,29,30)
InChI Key MCIDWGZGWVSZMK-UHFFFAOYSA-N
Immunopharmacology Comments
Nemiralisib is being evaluated for immunomodulatory (anti-inflammatory) potential in clinical trials.
Immunopharmacology Disease
Disease X-Refs Comment References
Activated PI3K delta syndrome OMIM: 615513
Orphanet: ORPHA397596
 Phase 2 clinical candidate for this condition (see NCT02593539). In the 2nd quarter of 2020, GSK made the decision to terminate the nemiralisib APDS programme, in a prioritisation review of their development pipeline.
Asthma Disease Ontology: DOID:2841
OMIM: 600807
 Completed Phase 1 trial in asthma (see NCT01462617).
Chronic obstructive pulmonary disease Disease Ontology: DOID:3083
 Phase 2 clinical candidate for COPD (see NCT02522299). 1